We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Regeneron is now poised to step in and purchase this customer data, for $256 million.The sale includes 23andMe’s customer-facing genomics service arm, as well as its health and research arm.

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

After Foley Hoag’s prior updates regarding the chapter 11 bankruptcy cases of 23andMe Holding Co and its affiliated debtors ...

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Regeneron had previously been the winning bidder in a bankruptcy auction for virtually all of 23andMe’s assets, but it's now lost out after bidding was reopened. Back to Top Albany Business Review ...

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe’s assets for $256 million in ...

The case came after New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase 23andMe in a $256 million deal. That deal has since faced new challenges in ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder and former chief executive, Anne Wojcicki.